Last reviewed · How we verify
Niraparib oral tablets
At a glance
| Generic name | Niraparib oral tablets |
|---|---|
| Sponsor | MedSIR |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating Safety, Tolerability, and Metabolism of Niraparib (PHASE4)
- Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) (PHASE1)
- Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (PHASE2)
- Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (PHASE2)
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study (PHASE2)
- Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
- SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (PHASE2)
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niraparib oral tablets CI brief — competitive landscape report
- Niraparib oral tablets updates RSS · CI watch RSS
- MedSIR portfolio CI